The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
分析师的判决：14位专家眼中的细胞内疗法
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI) in the last three months.
在过去三个月中，有14位分析师公布了对细胞内疗法（纳斯达克股票代码：ITCI）的评级，提供了从看涨到看跌的不同视角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38.
在对12个月目标股价的评估中，分析师公布了对细胞内疗法的见解，将平均目标价定为88.86美元，最高估计为103.00美元，低估值为77.00美元。当前的平均价格上涨了10.55％，超过了之前的平均目标股价80.38美元。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：仔细观察
The...
通...
登录免费看全文
登录/注册